Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration.
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Genmab announces positive top-line Phase II results of ofatumumab in multiple sclerosis
Multiple sclerosis immunology: The healthy immune system vs the MS immune system.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis.
Rituximab for refractory digital infarcts and ulcers in systemic sclerosis.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Daclizumab for relapsing remitting multiple sclerosis.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Biogen Idec's long-acting beta interferon moves ahead in MS
HLA-DRα1 Constructs Block CD74 Expression and MIF Effects in Experimental Autoimmune Encephalomyelitis.
FDA denies Teva Copaxone generic trials petition
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in relapsing-Remitting Multiple Sclerosis
Title: Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis in the Randomised ADVANCE Study.
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis.

Pages